Free shipping on all orders over $ 500

Vanoxerine dihydrochloride

Cat. No. M3250
Vanoxerine dihydrochloride Structure
Synonym:

GBR-12909 dihydrochloride; I893 dihydrochloride

Size Price Availability Quantity
10mM*1mL in DMSO USD 33  USD33 In stock
5mg USD 30  USD30 In stock
10mg USD 40  USD40 In stock
50mg USD 95  USD95 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a piperazine derivative which is a potent and selective DRI (dopamine reuptake inhibitor). GBR-12909 binds to the target site on the DAT ~ 500 times more strongly than cocaine, but simultaneously inhibits the release of dopamine. This combined effect only slightly elevates dopamine levels, giving vanoxerine only mild stimulant effects. Vanoxerine has been researched for use in treating cocaine dependence both as a substitute for cocaine and to block the rewarding effects.

Chemical Information
Molecular Weight 523.49
Formula C28H32F2N2O.2HCl
CAS Number 67469-78-7
Solubility (25°C) DMSO 8 mg/mL
Storage 4°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Ying Zhu, et al. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

[2] Mihoko Hagiwara-Nagasawa, et al. Cardiohemodynamic and Arrhythmogenic Effects of the Anti-Atrial Fibrillatory Compound Vanoxerine in Halothane-Anesthetized Dogs

[3] Naomichi Matsumoto, et al. Vanoxerine, a new drug for terminating atrial fibrillation and flutter

[4] Antonio E Lacerda, et al. Vanoxerine: cellular mechanism of a new antiarrhythmic

[5] A Preti. Vanoxerine National Institute on Drug Abuse

Related Dopamine Receptor Products
SV 156

SV 156 is a potent and selective D2 dopamine receptor antagonist, with a Ki of 2.5 nM for hD2. SV 156 has approximately 40-fold binding selectivity for D2 dopamine receptors compared to the D3 receptor subtype.

Cyclo(glycyl-L-leucyl)

Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity.

Onzigolide

Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors.

CVL-871

CVL-871 is a partial agonist at dopamine D1/5 receptors and may be used in dementia-related studies.

Paliperidone palmitate

Paliperidone palmitate is the ester precursor compound of Paliperidone, a potent dopamine antagonist and 5-HT2A antagonist. Paliperidone is a potent dopamine antagonist and 5-HT2A antagonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vanoxerine dihydrochloride, GBR-12909 dihydrochloride; I893 dihydrochloride supplier, Dopamine Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.